ASX Announcements

November

16/11/2021   Exopharm to Present at Key Exosome Industry Event

October

27/10/2021  Quarterly Activities Report and Appendix 4C

26/10/2021  2021 AGM Notice of Meeting and Proxy

26/10/2021  2021 AGM Letter to Shareholders and Proxy

September

30/09/2021  Appointment of Company Secretary

27/09/2021  Exopharm LEAP Technology – Further Step Towards US Patent

08/09/2021 Exopharm LEAP Technology – Second Commercial Collaboration

03/09/2021  Change of Director’s Interest Notice – EM

01/09/2021  Change of Director’s Interest Notice – JW

01/09/2021  Change of Director’s Interest Notice – ID

01/09/2021  Cleansing Notice

01/09/2021  Application for quotation of securities – EX1

01/09/2021  Date of Annual General Meeting

01/09/2021  Initial Director’s Interest Notice – JK

August

31/08/2021  Dr Jenn King joins Exopharm Board

30/08/2021  Appendix 4G and Corporate Governance Statement

30/08/2021  FY2021 Appendix 4E and Annual Report 

26/08/2021  Science Webinar – Overcoming the Nucleic Acid Delivery Challenge

20/08/2021  Investor Webinar Presentation

02/08/2021  Notification regarding unquoted securities

July

27/07/2021  Quarterly Activities Report and Appendix 4C

02/07/2021  Partnering & Licensing Focus Continues

June

30/06/2021  Investor Presentation

03/06/2021  Exopharm LEAP Exosome Technology Granted 1st National Patent

May

06/05/2021  Appendix 2A

April

30/04/2021  Change in substantial holding – ID

30/04/2021  Cleansing Notice

30/04/2021  Appendix 2A

20/04/2021  Proposed issue of Securities – EX1

20/04/2021  Exopharm Receives Firm Commitments to Raise $12 million

16/04/2021  Investor Presentation – Delivering Transformative Medicines

16/04/2021  Quarterly Activities Report and Appendix 4

15/04/2021  Trading Halt

08/04/2021  Exopharm Shareholder Update – Revenue Focus in 2021 

08/04/2021  Appendix 3G

06/04/2021  LEAP Technology- Advanced EV Medicines from Blood Components

06/04/2021  Positive PLEXOVAL II Phase 1 Clinical Trial Results

01/04/2021  Securities Trading Policy 

01/04/2021  Preclinical Data from Osteoarthritis Animal Study

 

February

26/02/2021  Appendix 4D and Half Year Financial Report

26/02/2021  Securities Trading Policy

16/02/2021  Exopharm presents at Bio CEO & Investor Digital Conference

10/02/2021  Change of Director’s Interest Notices – JW and ID

09/02/2021  Substantial Shareholder notices – amendment

08/02/2021  Response to ASX Price and Volume Query

January

29/01/2021  Exopharm Quarterly Activities Report and Appendix 4C

21/01/2021  Progress Points To Partnering Readiness

05/01/2021  Initial Director’s Interest Notice – EM

05/01/2021  Final Director’s Interest Notice – DP

05/01/2021  Exopharm Board Changes

04/01/2021  Change in substantial holding

04/01/2021  Becoming a substantial holder

04/01/2021  Lapse of Performance Rights

December

30/12/2020   Response to ASX Price and Volume Query

23/12/2020   Change of Director’s Interest Notice

22/12/2020   Shareholder Update

18/12/2020   Appendix 2A

11/12/2020   Release of Securities from 24 Month Escrow

02/12/2020   Change of Director’s Interest Notice

02/12/2020   Cleansing Notice

02/12/2020   Appendix 2A

November

30/11/2020   Results of Meeting

13/11/2020   Change of Registered Office Address

11/11/2020   Exopharm to Present at Key Exosome Industry Event

09/11/2020   Appendix 2A, Appendix 3G and Cleansing Notice

October

29/10/2020   Letter to Shareholders – Annual General Meeting

29/10/2020   Notice of Annual General Meeting/Proxy Form

29/10/2020   Results of Extraordinary General Meeting

27/10/2020   September Quarterly Report and Appendix 4C

22/10/2020   Plexoval II First Dosing and $2.1m R&D Rebate Received

06/10/2020   Annual General Meeting Date and Director Nominations

September

24/09/2020   Letter to Shareholders

24/09/2020   Notice of Extraordinary General Meeting/Proxy Form

18/09/2020   Shareholder Update: Investor Deck

17/09/2020   Change in Substantial Holding

15/09/2020   Proposed Issue of Securities

15/09/2020   Appointment of Manufacturing Expert & Corporate Advisor

14/09/2020   Annual Report

09/09/2020  Cleansing Notice

08/09/2020  Appendix 2A

August

27/08/2020   Proposed Issue of Securities

27/08/2020   Proposed Issue of Securities

27/08/2020   Exopharm Raises $10M in Well-supported Placement

26/08/2020   Appendix 4G and Corporate Governance Statement FY 2020

26/08/2020   Appendix 4E – Preliminary Final Report for Year Ended 30 June 2020

21/08/2020   Trading Halt Announcement

21/08/2020   Investor Presentation

19/08/2020   Shareholder Update

July

30/07/2020   June 2020 Quarterly Activities Report and Appendix 4C

22/07/2020   Shareholder Update

21/07/2020   Monsoon Communications Morning Twilight Briefing Webinar

June

16/06/2020   Company Secretary and services update

12/06/2020   Top 20 Shareholders Report 

12/06/2020   Additional IP empowers Exopharm’s engineered exosome pipeline

May

28/05/2020   Shareholder Update and Webinar

25/05/2020   Plexaris product engineered to deliver anti-cancer drug

April

24/04/2020   March 2020 Appendix 4C and Quarterly Report

01/04/2020   Plexoval Update

March

26/03/2020    Shareholder Update

05/03/2020   Investor Deck

February

24/02/2020   Statement clarification

20/02/2020   APPENDIX 4D – Interim Financial Report for the half year to 31 December 2019

20/02/2020   Cevaris testing shows positive results in bladder control model

19/02/2020   Cevaris testing shows positive results in models of erectile dysfunction

14/02/2020   Media Release: Erectile Dysfunction a Potential Target for Exopharm’s Exosomes

12/02/2020   Independent Plexaris and Cevaris testing shows positive and unique results

10/02/2020   Shareholder Update. Exopharm in 2020. News, Deals and Clinical Trials

05/02/2020   Investor Deck

January

29/01/2020   December 2019 Quarterly Activities Report and Appendix 4C

28/01/2020   Plexoval Update – World First Human Clinical Trials

November

25/11/2019   Key Management Contracts

18/11/2019   Results of AGM Meeting 2019

14/11/2019   Development Program Update

01/11/2019   Investor Deck, November 2019

October

28/10/2019   Appointment of Chief Commercial Officer

25 /10/2019  Shareholder Newsletter – October

25/10/2019   Quarterly 4c

17/10/2019   Notice of Annual General Meeting

17/10/2019   Annual Report

16/10/2019   Notice of Change of Interests of Substantial Holder

September

16-09-2019   Change of Director’s Interest Notice – Appendix 3Y

16/09/2019   Issue of Shares and Appendix 3B

09/09/2019   Results of General Meeting

August

30/08/2019   Appendix 4E and Annual Financial Report FY 2019

30/08/2019   Appendix 4G and Corporate Governance Statement FY 2019

26/08/2019   Plexoval Exosome Wound Healing Human Study Starts

19/08/2019   Appendix 3Y. Change of Director’s Interest Notice

19/08/2019   Appendix 3B. New Issue Announcement

16/08/2019   Closure of Offer Under the Share Purchase Plan

13/08/2019   Application for Quotation of Additional Securities and Agreement

08/08/2019   Notice of General Meeting

01/08/2019   Issue of Placement Shares

July

29/07/2019   EX1 ASX Announcement – Upcoming Release of Shares from Escrow

25/07/2019   Share Purchase Plan (SPP) Offer Document

25/07/2019   Cleansing Statement – Notice under ASIC Class Order [CO 09/425]

25/07/2019   Exopharm Appendix 4C – June Quarter

24/07/2019   Investor Deck Placement and Share Purchase Plan

24/07/2019   Share Placement and Share Purchase Plan Announcement

22/07/2019   Exopharm Secures Ethics Approval for the Plexoval Clinical Trial

22/07/2019   Trading Halt

19/07/2019   Appendix 3B New Issue Announcement

05/07/2019   Escrow Release

May

23/05/2019   Upcoming Release of Shares from Escrow

22/05/2019   Acceleration of Development Activities

April

30/04/2019   March 2019 Quarterly Activities Report and Appendix 4C

09/04/2019   Investor Presentation

01/04/2019   April 2019 Market Update

March

27/03/2019   Explainer: The critical bottleneck of exosome isolation and the power of Exopharm’s LEAP technology

February

21/02/2019   Dec 2018 Half-Yearly Report and Appendix 4D

05/02/2019   Positive outcomes from initial animal studies of Plexaris and Exomeres

January

31/01/2019   January 2019 Quarterly Cash Flow Report

31/01/2019   December 2018 Quarterly Activities Report